Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial. Here we find that hemizygous deletion of the PIK3R1 gene encoding p85α is a frequent event in breast cancer, with PIK3R1 expression significantly reduced in breast tumors. PIK3R1 knockdown transforms human mammary epithelial cells, and genetic ablation of Pik3r1 accelerates a mouse model of HER2/neu-driven breast cancer. We demonstrate that partial loss of p85α increases the amount of p110α-p85 heterodimers bound to active receptors, augmenting PI3K signaling and oncogenic transformation. Pan-PI3K and p110α-selective pharmacological inhibition effectively blocks transformation driven by partial p85α loss both in vitro and in vivo. Together, our data suggest that p85α plays a tumor-suppressive role in transformation, and suggest that p110α-selective therapeutics may be effective in the treatment of breast cancer patients with PIK3R1 loss.
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial. Here we find that hemizygous deletion of the PIK3R1 gene encoding p85α is a frequent event in breast cancer, with PIK3R1 expression significantly reduced in breast tumors. PIK3R1 knockdown transforms human mammary epithelial cells, and genetic ablation of Pik3r1 accelerates a mouse model of HER2/neu-driven breast cancer. We demonstrate that partial loss of p85α increases the amount of p110α-p85 heterodimers bound to active receptors, augmenting PI3K signaling and oncogenic transformation. Pan-PI3K and p110α-selective pharmacological inhibition effectively blocks transformation driven by partial p85α loss both in vitro and in vivo. Together, our data suggest that p85α plays a tumor-suppressive role in transformation, and suggest that p110α-selective therapeutics may be effective in the treatment of breast cancer patients with PIK3R1 loss.
PI3K | p85 | breast cancer | targeted therapy P hosphatidylinositol 3-kinases (PI3Ks) are critical coordinators of the cellular response to extracellular signals. Of these, class IA PI3Ks are heterodimeric enzymes containing a p110 catalytic and a p85 regulatory subunit (1) . The genes PIK3CA, PIK3CB, and PIK3CD, respectively, encode p110α, p110β, and p110δ, and PIK3R1, PIK3R2, and PIK3R3, respectively, encode the regulatory isoforms p85α, p85β, and p55γ. In the absence of activating signals, the interaction between p85 and p110 stabilizes and inhibits p110 catalytic activity (2) . In the presence of growth factors or other signals, ligand binding to receptor tyrosine kinases (RTKs) promotes receptor activation. The p85 subunit binds to activated RTKs, recruiting p110 to the plasma membrane, where a conformational change induced by binding relieves inhibition of p110 catalytic activity.
PI3K pathway hyperactivation is one of the most frequent events in human cancers, commonly resulting from activating PIK3CA mutations, RTK mutation or amplification, or loss of the PI3K antagonist PTEN (3) . The contribution of the regulatory isoforms to tumorigenesis has only recently been considered. Somatic mutations in PIK3R1 have been reported in glioblastoma and endometrial cancer, most of which are substitutions or indels in the iSH2 domain of p85α that contacts p110 (4) . These mutants typically bind and stabilize p110, but cannot inhibit p110 catalytic activity (5) .
Accumulating evidence also suggests that changes in p85α levels can modulate PI3K activation. In mice, partial loss of p85 isoforms improves insulin sensitivity (6) . In some tissues, p85 is present in excess of p110, and monomeric free p85 may act as a negative regulator of PI3K signaling (7) . Overexpression of p85α in myotubes reduced insulin-stimulated PI3K/AKT activation (8) , and p85α overexpression in mice decreased skeletal muscle insulin signaling (9) . Loss of p85α has also been proposed to play a role in cancer. PIK3R1 underexpression was detected in human breast cancer and, in mice, liver-specific Pik3r1 deletion led to the development of PI3K pathway-activated hepatocellular carcinoma (10, 11 ).
Here we demonstrate that p85α functions as a tumor suppressor. PIK3R1 is lost at the genomic and mRNA expression levels in breast cancer. We demonstrate that p85α depletion increases PI3K/AKT signaling and transformation in vitro, and accelerates tumor development in a mouse model of HER2-driven breast cancer. We provide evidence that partial p85α loss increases the ratio of signaling p85-p110 heterodimers bound to activated HER family receptors. Last, we show that p110α-selective inhibition blocks transformation driven by p85α loss. Our results indicate that p85α is a clinically relevant tumor suppressor and suggest that isoform-selective PI3K inhibitors may be effective in the treatment of cancers characterized by p85α expression loss.
Results

PIK3R1
Expression Is Reduced in Breast Cancers. To determine whether p85α may play a tumor-suppressive role in breast cancer, we evaluated copy-number loss or mutation of PIK3R1 in publicly available datasets (12, 13) . Such alterations in PIK3R1 occurred in 23 and 28% of breast cancers, respectively, with the majority of these being hemizygous PIK3R1 loss (Fig. 1A) . PIK3R1 mRNA expression was also significantly reduced by 50 to 77% in breast cancer samples (Fig. 1B and Table S1 ) (14) (15) (16) (17) . Together, these results indicate that PIK3R1 is decreased in human breast cancer.
PIK3R1 Knockdown Transforms Human Mammary Epithelial Cells. To study whether partial p85α loss transforms in vitro, we used hTERT immortalized human mammary epithelial cells (HMECs) that express a dominant-negative p53 mutant (DDp53). These Significance Phosphatidylinositol 3-kinase (PI3K) pathway hyperactivation is a common event in cancer, and understanding alterations in this pathway is critical. Recently, the p85 regulatory subunit of PI3K has come into focus as a novel pathway component targeted in cancers. We find that decreased p85α contributes to transformation of in vitro and in vivo models of breast cancer. We provide evidence that partial loss of p85α increases the binding of p110α-p85 signaling complexes to activated receptors, thereby augmenting PI3K pathway output. Our findings indicate that p85α loss may be transforming in any context where PI3K is activated. Additionally, they implicate a role for monomeric free p85 as a negative regulator of PI3K signaling.
HMECS are not transformed, as they are unable to form colonies in soft agar. Expression of cancer-associated mutant PIK3CA alleles transforms these cells (18) . To address whether decreased PIK3R1 expression transforms mammary cells, we generated DDp53-HMEC lines with stable PIK3R1 knockdown. PIK3R1-targeted shRNAs reduced p85α expression ( Fig. 2A and Fig. S1 A and B) . Starvation followed by EGF stimulation increased and sustained PI3K/AKT signaling in shPIK3R1 cells, as indicated by increased AKT, PRAS40, GSK3β, S6K, and S6 effector phosphorylation ( Fig. 2A) . To assess the functional effect of augmented PI3K/AKT activation in shPIK3R1 cells, we determined the ability of these cells to undergo anchorage-independent growth. Both shPIK3R1 lines grow in soft agar (Fig. 2B) . Expression of PIK3R1 rescue constructs restores p85α protein levels, attenuates PI3K/AKT pathway activation as indicated by reduced effector phosphorylation ( Fig. 2C and Fig. S1 A and B) , and partially rescues HMEC transformation mediated by PIK3R1 knockdown (Fig. 2D) . Thus, reduction of PIK3R1 expression activates PI3K/AKT signaling and transforms breast cancer cell lines.
Because the increased signaling in shPIK3R1 DDp53-HMECs was largely dependent on growth factor stimulation, we investigated whether reduced p85α cooperates with PI3K-activating oncogenes to promote signaling and transformation. We next generated shPIK3R1 DDp53-HMECs stably expressing neuT, an activated form of HER2/neu. Expression of neuT increases PI3K/AKT activation; concomitant PIK3R1 knockdown further enhances pathway activation and enhances colony formation, by increasing colony number and size (Fig. 2 E 
-G).
Transformation Driven by PIK3R1 Knockdown Is Mediated by Signaling Through p110α. The PI3K catalytic isoforms play divergent roles in oncogenic signaling, which can inform clinical use of isoformselective PI3K inhibitors. Accordingly, we used the pan-PI3K inhibitor GDC-0941, the p110α-selective inhibitor BYL-719, and Means ± SEM are shown; n = 3. *P < 0.05, **P < 0.01, ****P < 0.0001; unpaired t test.
the p110β-selective inhibitor to determine the contribution of p110 isoforms to the transformation of shPIK3R1 DDp53-HMECs (3). Treatment with either GDC-0941 or BYL-719, but not KIN-193, effectively blocks colony formation and PI3K/AKT effector signaling in shPIK3R1 HMECs ( Fig. 3 A, B , and E). Thus, transformation with p85α depletion is largely mediated through p110α and not p110β. Although it has been demonstrated that HER2/neu-driven transformation relies on p110α (19) , coexisting genetic events can shift PI3K isoform dependency (20) . Therefore, we determined which PI3K catalytic isoform mediates HER2/neu-driven transformation in the context of partial p85α loss. Anchorage-independent growth assays suggest that pan-PI3K or p110α-selective inhibitors block colony formation and attenuate PI3K/AKT effector signaling, whereas p110β-selective inhibition does not (Fig. 3 C, D, and F) . Thus, augmented PI3K/AKT signaling in and transformation of shPIK3R1 HMECs with or without HER2/neu activation are primarily mediated by p110α.
Pik3r1 Ablation Increases Tumor Formation in Genetically Engineered
Mouse Models. We next used genetically engineered mouse (GEM) models to examine whether loss of p85α contributes to mammary epithelial cell transformation in vivo. Mice bearing a floxed Pik3r1 allele (21) were crossed with mammary-specific MMTV-Cre mice (22) . The resulting MMTV-Cre; Pik3r1 +/loxP and MMTV-Cre; Pik3r1 loxP/loxP mice have mosaic ablation of one or both Pik3r1 alleles in luminal mammary epithelial cells, and will hereafter be referred to as MMTV-Cre; Pik3r1 +/− and MMTV-Cre; Pik3r1 −/− , respectively (Fig. S2A) . Pik3r1 ablation did not alter mammary gland development throughout pubertal development or lobuloalveolar development during pregnancy (Fig. S2B) . However, nulliparous MMTV-Cre; Pik3r1 +/− and MMTV-Cre; Pik3r1
females developed spontaneous mammary tumors with diverse pathology with an average latency of 14.1 mo, average survival of 14.4 mo, and penetrance of 90% (9/10) ( Fig. S2C and Table S2 ). Metastasis of the primary tumor to the lung was observed in 11% (1/9) of the mice with spontaneous mammary tumors (Fig. S2D) . Together, these observations suggest that p85α depletion alone is sufficient for mammary tumor development and metastasis in mice.
To further study the contribution of p85α loss to in vivo mammary tumorigenesis, we combined a GEM model of HER2/ neu-driven breast cancer with the conditional Pik3r1 knockout mice. We bred Pik3r1 floxed mice with MMTV-NIC mice, which express a bicistronic transgene consisting of an activated HER2/ neu allele and Cre recombinase under control of the MMTV LTR promoter (23) . The resulting MMTV-NIC; Pik3r1 +/− and MMTV-NIC; Pik3r1 −/− mice have ablation of one or both Pik3r1 alleles in the same luminal mammary epithelial cells that express oncogenic HER2/neu. These strains will hereafter be referred to as NIC, NIC; Pik3r1 (Fig. 4 A and B) . These data indicate that p85α depletion significantly reduces the latency of HER2/neu-driven mammary tumorigenesis in mice.
We examined whether partial p85α loss affected HER2/neudriven mouse mammary tumors. Tumors from mice of all three genotypes had solid nodular carcinoma histology and tumors of similar weight (Fig. S3 A and B) . A trend toward higher incidence of lung metastasis in mice with Pik3r1 deletion and an increase in tumor number was observed exclusively in heterozygous NIC; Pik3r1 +/− mice ( Fig. S3 C and D) . However, NIC; Pik3r1 +/− and NIC; Pik3r1 −/− tumors had nearly double the proliferation indices (Fig. S3E) . Together, these results demonstrate that reduced p85α expression increases the proliferative capacity of HER2/neu tumor cells, correlating with the reduced time to mammary tumor onset.
Growth of Mammary Tumors with Pik3r1 Ablation Is Blocked by p110α-Selective Inhibitors. Because pan-PI3K or p110α-selective inhibitors blocked HMEC transformation driven by partial p85α loss, we determined whether these agents could inhibit growth of HER2/ neu-driven mammary tumors with p85α depletion. Primary tumors were excised from a NIC; Pik3r1 +/− donor female and orthotopically transplanted into NCrNu female recipients. Recipient mice were treated daily with vehicle, GDC-0941, BYL-719, or KIN-193, all without affecting animal body weight (Fig. S3F) . Treatment with GDC-0941 or BYL-719 significantly reduced tumor growth, whereas KIN-193 had no effect (Fig. 4C ). Tumors treated with either GDC-0941 or BYL-719 exhibit reduced AKT and S6 phosphorylation, a lower proliferative index, and the presence of TUNEL-positive apoptotic nuclei (Fig. 4 D and E and Fig. S3G ). These results indicate that p110α-selective and pan-PI3K inhibitors attenuate PI3K/AKT signaling and block in vivo tumor growth in the context of reduced p85α expression.
PIK3R1 Knockdown Increases p85-p110α Bound to Activated RTKs.
We next examined the mechanism by which reduced p85α levels could increase PI3K/AKT signaling output and mediate transformation. Despite publications suggesting that p85α may increase PTEN phosphatase activity (24, 25) or PTEN stability (11), we were unable to confirm p85-PTEN association (Fig. S4 A-C) , p85α-mediated reduction in PTEN protein or mRNA levels ( Fig. 2E and Figs. S1A and S4D ), or p85α-mediated effect on the lipid phosphatase activity of PTEN (Fig. S4 E and F) . PIK3R1 knockdown also did not affect EGFR phosphorylation, internalization, or degradation (Fig. S5) .
However, monomeric, free p85 has been shown to function as a potent p110 inhibitor (7) . Activation of RTKs recruits p85-p110 heterodimers to the plasma membrane, which initiates a conformational change to p110α that results in its activation. We therefore considered the possibility that partial p85α loss enhances the specific pool of p85-p110 heterodimers that bind to and potentiate RTK-mediated signal transduction. PIK3R1 knockdown increases the ratio of p85-p110α heterodimers associated with the RTK ErbB3 (Fig. 5 A and B) . PIK3R1 knockdown also increases p110α-ErbB3 association, despite a 50% reduction in p85 association with ErbB3 ( Fig. 5 C and D) . Increased p85-p110 association with ErbB3 activates AKT (Fig. 5 E-G) . These results demonstrate that partial PIK3R1 knockdown increases the association of remaining p85 with p110 and ErbB3, promoting oncogenic activation of PI3K/AKT effector signaling.
Discussion
Studies from mouse models with knockout of p85 regulatory subunits have had surprising results. Mice with Pik3r1 ablation (deleting p85α, p55α, and p50α) (26) , just p85α (27) , p55α and p50α (28) , or Pik3r2 (deleting p85β) (29) all exhibit hypoglycemia, increased sensitivity to insulin, and augmented insulin-mediated Akt activation. Here we present evidence that PIK3R1 knockdown transforms HMECs, increasing their proliferation and activation of the PI3K pathway in response to EGF stimulation. We show that in a mouse model of Her2/neu-driven breast cancer, mammaryspecific Pik3r1 ablation reduces the latency of mammary tumor development, increases tumor burden, and up-regulates PI3K pathway activation.
Because p85 stabilizes the p110 subunit and recruits it to the cell membrane (2), it seems paradoxical that a reduction in p85 Fig. S3G . Means ± SEM are shown; all groups n = 8. **P < 0.01, ***P < 0.001, ****P < 0.0001; unpaired t test.
might lead to increased PI3K output. Our data support a model where PIK3R1 knockdown selectively reduces a pool of free p85α, allowing for increased binding of p85-p110 signaling-capable heterodimers to activated RTKs and increased PI3K output (Fig. 5H) . Accumulating evidence indicates an imbalance between the regulatory and catalytic PI3K subunits: Immunodepletion suggests that the ratio of p85-p110 dimers to free p85 monomers is 2:1 (6).
Quantitative mass spectrometry has shown that endogenous p85 and p110 are present in equal amounts in mouse muscle, liver, fat, and spleen, whereas p85 is present in a twofold excess over p110 in the brain (30) . Our data suggest that mammary epithelial cells have p85 in excess of p110, and that this free p85 monomer plays a role in the regulation of PI3K activity. Free p85 can homodimerize, with all four SH2 domains in a flexible conformation. This flexible p85 SH2 conformation (31) is likely to enhance avidity for the nine pYXXM motifs in IRS1 in comparison with the p85-p110 heterodimer, where only the C-terminal p85 SH2 domain has high affinity for the IRS1 motifs (the N-terminal SH2 domain interacts with p110 in a manner that impairs but does not eliminate binding to pYXXM motifs). The clustering and sequestration of IRS1 by the p85 homodimer (32) likely contribute to the ability of free p85 to suppress insulin signaling. Reports have linked p85α to the control of the activity or stability of PTEN. Mice with liver-specific Pik3r1 knockout have reduced total PI3K activity but an increase in Akt activation and sustained PIP 3 production; the lipid phosphatase activity of PTEN was found to be reduced (24) . Addition of increasing amounts of p85α has also been shown to augment PTEN lipid phosphatase activity in vitro (25) . Furthermore, p85α and PTEN have been reported to directly interact (33). We did not find an effect of PIK3R1 knockdown on the lipid phosphatase activity of PTEN immunoprecipitates in vitro, nor did we detect a reduction in PTEN protein or mRNA in shPIK3R1 HMECs or in tumors from NIC; Pik3r1 −/− mice. It may be that PTEN loss is a secondary event, rather than driving transformation mediated by p85α loss.
A number of recent reports have described genomic alterations in PIK3R1. Point mutations in the nSH2 and iSH2 p85α domains activate PI3K signaling and promote tumorigenesis in models of glioblastoma (34) . Deletion of PIK3R1 exon 13 was detected in human ovarian and colon cancer cell lines and primary tumors (35) . Somatic PIK3R1 mutations have been found in a variety of cancers with a frequency of 2 to 24% (4, 10) . A subset of cancer-associated PIK3R1 mutations codes for premature truncation of the p85α protein (5), but the transforming mechanism of p85α truncation is unknown. Truncation mutants lose the C-terminal SH2 domain, and thus p85 homodimers with these truncations may not be as effective at binding IRS1. The remaining full-length p85α allele, in cases with hemizygous p85α loss, likely binds more readily to p110α and promotes recruitment to IRS1. Thus, we speculate that truncation mutants that lack the C-terminal SH2 domain might have a similar effect on PI3K signaling as reduction in p85α, and may transform cells by freeing binding spaces on activated RTKs for signaling-proficient p110-p85α heterodimers.
Our data demonstrate that transformation mediated by p85α loss occurs primarily by signaling through p110α. In mice, treatment with pan-and p110α-specific inhibitors slows the growth of transplanted NIC tumors with Pik3r1 ablation. The data presented here indicate that in cancers where expression of p85α is reduced or functionally inactivated, treatment with p110α-specific inhibitors such as BYL-719 is as effective as pan-PI3K inhibition. Importantly, this is one case where therapeutic targeting of loss of a tumor suppressor is possible due to identification of activated downstream pathways.
Materials and Methods
For additional information, please refer to SI Materials and Methods.
Publicly Available Clinical Data. cBio (www.cbioportal.org) was used to query The Cancer Genome Atlas (TCGA) breast invasive carcinoma studies. The Oncomine database (https://www.oncomine.org) was queried for expression of PIK3R1 in breast cancer microarray studies. Data were converted to raw expression levels of PIK3R1 by taking the inverse log2, and then normalized to the mean raw PIK3R1 expression level of normal breast tissue.
Protein Lysate Preparation, Immunoprecipitation, and Immunoblotting. Cells were lysed in Nonidet P-40 lysis buffer (137 mM NaCl, 20 mM Tris·HCl, pH 8.0, 0.2 mM EDTA, 10% glycerol, 1% Nonidet P-40) with protease and phosphatase inhibitors. For preparation of lysates from tissue, tissue was snap-frozen and then homogenized in Nonidet P-40 lysis buffer using 0.5-mm zirconium oxide beads (Next Advance) in an air-cooling Bullet Blender (Next Advance). For immunoprecipitation of Flag-ErbB3 from HMECs, cells were rinsed with PBS and starved for 4 h before lysis. Anti-Flag beads were incubated with 1 mg lysate, washed, and resuspended in SDS/DTT sample buffer. Proteins were separated by SDS/PAGE and transferred onto nitrocellulose membranes. Proteins of interest were visualized and quantified (Odyssey; LI-COR) after primary antibody incubation: vinculin and Flag (Sigma), pan-p85 and p85α (Millipore), p85β (Santa Cruz), Flag (OriGene), ErbB2 (Calbiochem), and p110α, p110β, HA, ErbB3, PTEN, p-AKT Histology and Immunohistochemistry. FFPE tumors were sectioned and mounted. Hematoxylin and eosin staining was performed by the Harvard Medical School Rodent Histopathology Core. Immunohistochemical staining was performed using a sodium citrate antigen retrieval method (Boston BioProducts). Slides were incubated with the following primary antibodies overnight: p85α (EMD Millipore), p-AKT S473 (CST), p-S6 S235/236 (CST), and Ki67 (Vector Labs). Antibody signal was detected using biotinylated goat anti-rabbit IgG secondary antibody and DABdeveloped (Vector Labs), and slides were counterstained with hematoxylin (Vector Labs). For TUNEL, the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit was used (EMD Millipore) followed by a counterstain with methyl green (Vector Labs). Slides were imaged (Nikon; Eclipse E600 microscope).
Growth Factor Stimulation Time-Course Assays. Cells were rinsed with PBS and starved in HMEC starvation medium (DMEM/F12 GlutaMAX with penicillin/ streptomycin). Human recombinant EGF was used at 20 ng/mL to stimulate cells.
Anchorage-Independent Growth Assays. Cells were plated in a solution of 0.3% agar in HMEC growth medium on top of a base layer of 0.6% agar in DMEM. Images of unstained colonies were taken (Nikon; SMZ-U). Plates were then stained with 0.5 mg/mL iodonitrotetrazolium chloride (Sigma); pictures of stained plates were taken (Alpha Innotech; AlphaImager EP transilluminator).
Mice. MMTV-Cre (22) 
